

## INTRODUCTION

- Duchenne muscular dystrophy (DMD) is a rare, genetic disease characterized by progressive muscle degeneration and weakness
- As the disease progresses, individuals with DMD become increasingly dependent on caregivers
- While improvements have been made in supportive and rehabilitative care, there is still no cure for DMD
- Because of the progressive nature of DMD, successful treatment may slow functional decline for treated patients
- It is challenging to assess whether the slowing of a patient’s functional decline changes the patient’s quality of life
- This study explores the impact of both the incremental loss of muscle function and change in ability to perform activities of daily living have on patient and caregiver quality of life

## RESULTS

TABLE 1. Patient age and current level of function			
Caregiver study ID	Patient age, y	Activities the patient can do without any help	Activities the patient requires help with
B01	18	Playing video games and playing on a phone or iPad	Toileting, brushing teeth, scratching anything that is not within limited range of motion
B02	18	Playing video games, using phone, and pushing buttons on remote control	Toileting, hygiene, getting dressed, being fed, repositioning at night
B03	22	Feeding self, washing parts of themselves in shower, using a computer, playing video games, painting nails	Getting food, taking medicine, getting on toilet, wiping, getting in and out of shower, washing hair, getting things out of backpack, getting desk set up
B04	23	Brushing teeth, feeding self	Writing, grooming, dressing, toileting, getting in and out of bed, moving arms in bed, repositioning in bed
B05	30	Feeding self, using computer, playing video games, drinking with a straw	Lifting arms to face, repositioning self
B06	24	Playing video games, using a mouse, playing board games, drinking bottle of water	Putting blankets on and cutting meat
B07	22	Using computer, using phone, pushing up glasses, using wheelchair joystick, writing with pencil or pen	Dressing, toileting, showering, brushing teeth, feeding, lifting a glass
B08	24	Scooting, feeding self, using urinal to pee, going to college	Preparing food, dressing, undressing, moving computer around, transferring to shower chair, getting on and off the toilet, showering, washing hair, scratching back, scratching head

FIGURE 1. Impact of changes in ability to self-feed on quality of life



FIGURE 2. Abilities that depend on arm function, as reported by caregivers

Muscle function	Arm function													
	Raise hand to face						Raise hand to mouth	Engage arm muscles	Lift forearms off lap	Lock out elbows to push off		Lateral arm movement	Reach	Lift weight
	Scratch itch	Protect face	Get hair out of mouth	Push glasses up	Brush teeth	Have a phone conversation not on speaker	Self-feed	Get dressed	Get dressed	Get dressed	Transfer	Drive in adaptive car	Use full keyboard	Use phone
Abilities that depend on muscle function														
Impact on patient and caregiver (representative quotes)	“He’ll get mosquito bites and...he can’t scratch it.”	“...he wouldn’t be able to put his hands up and protect his face or turn his head in time.”	“Imagine having a hair in your mouth you can’t get it out, you have to rely on somebody else to find it, get it for you. I was just like; this disease is relentless.”	“I just worry, is somebody gonna be able to push his glasses up, you know, that little thing, if he needs it.”	“He cannot brush his teeth himself.”	“You have no privacy whatsoever anyway, and then you can’t even talk to your friends without being on a speakerphone.”	“Being fed a meal as a...17/18-year-old kid is kind of humiliating.”	“It’s like putting a pillowcase on the flattest, limpest pillow you could ever have.”	“So that small bit of help that he could do with helping to get a shirt on...to be able to lift his, his hands, his forearms up a bit. He can’t do that anymore.”	“He would scoot...his bum up a little bit so that I can pull on underwear or shorts or pants. and that was his arm muscles.”	“He used to be able to scooch forward on his bed, he can’t do that.”	“He started cornering much more slowly out of fear that if...his elbow fell off his armrest, he wouldn’t be able to get it back up and be able to drive.”	“...he can reach the lower couple of rows of keys, but he can’t reach the upper row with the numbers.”	“He cannot lift that anymore... we had to work around it...my arms are now his arms.”

## CONCLUSIONS

- Independent activities of daily living for patients with DMD undergo a qualitative degeneration comprised of incremental and meaningful losses in function
- There are a number of impactful and meaningful functional losses in patients with DMD that affect quality of life and are not captured in clinical trial outcomes
- Capturing and quantifying the nuances of loss in patients with DMD will provide a more complete picture of the function of people with DMD for regulators and payers
- As part of this study, additional qualitative interviews are currently being conducted with patients treated with givinostat and their caregivers. Future analyses will explore the impact of the maintenance of independence on quality of life once all interviews have been conducted

### ACKNOWLEDGMENT AND FUNDING

This study is sponsored by Italfarmaco S.p.A. Editorial support was provided by Jennifer Ayala, PhD, CMPP, from Citrus Health Group, Inc. (Chicago, Illinois), and was funded by ITF Therapeutics, LLC.

### AUTHOR DISCLOSURES

**ML and MGC:** Employees of Red Nucleus.  
**EM:** Received grants or research support from Astellas Pharma, BioMarin Pharmaceutical, Capricor Therapeutics, Catabasis Pharmaceuticals, Edgewise Therapeutics, Italfarmaco S.p.A., Pfizer, PTC Therapeutics, and Santhera Pharmaceuticals and consulting fees from Sarepta Therapeutics, Astellas Pharma, Avidity Biosciences, BioMarin Pharmaceutical, Bristol Myers Squibb, Capricor Therapeutics, Catabasis Pharmaceuticals, Edgewise Therapeutics, Eli Lilly, Epirium Bio, Entrada Therapeutics, Gilead Sciences, Halo Therapeutics, Italfarmaco S.p.A., Novartis, PepGen, Pfizer, PTC Therapeutics, Prosenza, and Santhera Pharmaceuticals.  
**FMC:** Principal investigator of the Vall d'Hebron University Hospital, Barcelona, site of the current study. **MLL:** Received research support from Italfarmaco S.p.A. **SP, SC, NC, and VD:** Employees of Italfarmaco S.p.A.

